S. Del Carlo

Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles

Parecoxib is an inactive pro-drug that is rapidly converted to valdecoxib, a selective cyclooxygenase (COX)-2 inhibitor registered for the management of post-operative pain in humans. Recent studies have suggested that parecoxib has excellent clinical efficacy and safety in veterinary species. The aim of the current study was to assess the pharmacokinetics of parecoxib and valdecoxib after intravenous (i.v.) and intramuscular (i.m.) administration. Seven healthy male Beagle dogs received 2.5 mg/kg parecoxib by either the i.v. or i.m. route in a cross-over design, with the alternative route of administration used 1 week later. The plasma concentrations of both analytes were detected according to a previously validated method using high performance liquid chromatography with fluorescence detection (HPLC-FL). No adverse effects were observed in any animal during the study. For both routes of administration, parecoxib was rapidly and almost completely converted to valdecoxib. The parecoxib/valdecoxib area under the curve (AUC) ratio for both routes of administration was 1.4. The half-life of valdecoxib was about 2 h, which was shorter than reported for humans, although the plasma concentrations following both routes of administration were likely to be effective for analgesia. The absolute bioavailability of parecoxib was 66%. The pharmacokinetic features of parecoxib make it suitable for treatment of acute pain in the canine species.

Development of an HPLC/UV assay for the evaluation of inhibitors of human recombinant monoacylglycerol lipase.

Monoacylglycerol lipase (MAGL) is a membrane-associated cytosolic serine hydrolase which catalyses the hydrolysis of the endocannabinoid 2-arachidonoylglycerol into arachidonic acid and glycerol. MAGL represents the link between the endocannabinoid and the eicosanoid system indeed its inhibition enhances endocannabinoid signalling and lowers eicosanoid production. Here we present a radioactive-free, sensitive and solid HPLC-UV based method to evaluate MAGL activity by using 4-nitrophenylacetate (4-NPA) as substrate. The enzymatic activity is measured by quantifying the 4-nitrophenol (PNP) (λ = 315 nm) formation on a C18 stationary phase. The method was validated by calculating IC50 values of the reference inhibitors JZL184, CAY10499 and JW642 and confirming the irreversible and non-competitive mechanism of inhibition for JZL184. Furthermore in order to resemble the catalytic conditions of MAGL at cell membrane level, the surfactant Triton X-100 was added, as a micelle forming agent and 4-nitrophenyldodecanoate (4-NPDo) was used as lipophilic substrate for MAGL. The data obtained confirmed that the HPLC method is an alternative, radioactive-free approach for the screening and characterization of new MAGL inhibitors. Finally this assay prevents, in an unequivocal manner, any interference related to the intrinsic absorbance of screened compounds or metabolites generated upon enzymatic cleavage which could seriously affect the assay readout.

Pharmacokinetics of the Tramadol Injective Formulations in Alpacas (Vicugna pacos)

The objective of the present study was to test the intravenous (IV) and intramuscular (IM) administration of tramadol to alpacas (Vicugna pacos). The study was a two-group, single-dose, two-treatment, two-period, randomized, open, balanced, cross-over design. After both administrations of tramadol to alpacas (2.5 mg/kg b.w.), plasma concentrations of tramadol and its main metabolites (M1, M2, and M5) were determined using an HPLC method. Moderate side effects were shown after IV administration. The IM bioavailability of the drug (81.5%) was within the generally accepted values for a positive bioequivalence decision (80–125%). The plasma concentrations of M1 and M5 were low, and the amounts of M2 produced were similar after both routes of administration. In conclusion, tramadol was rapidly and almost completely absorbed after IM administration, and its systemic availability was equivalent to IV injection. Hence, IM injection of tramadol is a useful and good alternative to IV injection in alpacas.